Tirzepatide Weight Loss Dallas

Physician-guided Zepbound® and tirzepatide weight management with dual board-certified medical oversight, InBody body-composition monitoring and a focus on losing fat while protecting muscle.

Medical Weight Loss in Dallas

Tirzepatide is a dual GIP and GLP-1 receptor agonist and the active medication in Zepbound® and Mounjaro®. For appropriate patients, it can produce substantial weight loss by influencing appetite, satiety and metabolic signaling. At Sanjiva Medical Spa, treatment is guided by a physician board certified in both Internal Medicine and Obesity Medicine.

What Is Tirzepatide?

Tirzepatide is a once-weekly medication that activates both GIP and GLP-1 receptors. These pathways influence appetite, satiety, food intake and glucose regulation. Tirzepatide is the active ingredient in Zepbound and Mounjaro, but the two brands have different FDA-approved indications.

That dual-receptor mechanism is one reason tirzepatide has become an important medication in modern obesity treatment. It should still be viewed as one component of a broader medical weight-management strategy—not a replacement for nutrition, resistance training and long-term planning.

Zepbound vs Mounjaro: What’s the Difference?

Both Zepbound and Mounjaro contain tirzepatide. Zepbound is the brand specifically FDA approved for chronic weight management in eligible adults and also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is FDA approved for improving glycemic control in patients with type 2 diabetes.

Zepbound®

Tirzepatide for chronic weight management in qualifying patients. It also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

Mounjaro®

Tirzepatide FDA approved for type 2 diabetes. Although patients commonly search “Mounjaro for weight loss,” Zepbound is the tirzepatide brand specifically approved for chronic weight management.

How Much Weight Can You Lose With Tirzepatide?

Tirzepatide has produced substantial average weight reduction in clinical trials. In SURMOUNT-1, adults with obesity or overweight without diabetes lost approximately 15% to 21% of starting body weight on average at 72 weeks depending on dose, with the highest-dose group averaging about 21% using the treatment-regimen estimand. Individual results vary.
~21% Average Weight Loss At the 15 mg dose in SURMOUNT-1 at 72 weeks using the treatment-regimen estimand. Results vary by dose, adherence and individual response.

For a person starting at 200 pounds, 20% represents approximately 40 pounds. But the scale alone cannot tell you whether those pounds came from fat, lean tissue or both.

The Sanjiva Difference: Lose Fat, Protect Muscle

The goal should not simply be to become lighter. During significant weight loss, preserving lean mass matters for strength, function and body composition. Sanjiva emphasizes adequate protein, resistance training and InBody monitoring when appropriate so we can look beyond scale weight.
Fat LossLook beyond total pounds
Muscle PreservationProtein + resistance training
Body CompositionTrack muscle, fat and visceral fat
MaintenancePlan beyond goal weight

Who May Be a Candidate for Zepbound?

Zepbound is used with reduced-calorie nutrition and increased physical activity for chronic weight management in eligible adults with obesity or adults with overweight who also have at least one weight-related condition. Whether tirzepatide is appropriate depends on your medical history, current medications, contraindications and treatment goals.

At Sanjiva, the question is not simply “Can I get tirzepatide?” The better question is: “Which weight-management strategy makes sense for my health, body composition and long-term goals?”

Why Choose Sanjiva for Tirzepatide in Dallas?

Sanjiva combines obesity-medicine expertise with practical body-composition monitoring. Treatment is guided by a physician board certified by both the American Board of Internal Medicine and the American Board of Obesity Medicine, with an emphasis on evidence-based medication selection, muscle preservation and sustainable maintenance.
Dual Board CertifiedInternal Medicine + Obesity Medicine
InBody 580Track fat, muscle and visceral fat
Medical OversightIndividualized prescription care
Long-Term StrategyWeight loss + maintenance

Tirzepatide vs Semaglutide: Which Is Better for Weight Loss?

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors. In the head-to-head SURMOUNT-5 trial, adults with obesity without diabetes lost an average of 20.2% with tirzepatide versus 13.7% with semaglutide at 72 weeks using maximum tolerated doses. Tirzepatide was superior for average weight and waist-circumference reduction in that trial.
TirzepatideDual GIP + GLP-1 receptor agonist.
Weight-management brand: Zepbound.
SemaglutideGLP-1 receptor agonist.
Weight-management brand: Wegovy.

That does not mean tirzepatide is automatically the right medication for every patient. Medical history, side effects, contraindications, treatment response, medication access and patient preference all matter.

Tirzepatide Side Effects & Safety

The most common side effects of Zepbound are gastrointestinal and can include nausea, diarrhea, vomiting, constipation, abdominal discomfort and indigestion. Dose escalation is gradual to improve tolerability. Tirzepatide is not appropriate for everyone, so medical screening and follow-up matter.

Zepbound carries a boxed warning regarding thyroid C-cell tumors observed in rats and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other important warnings and precautions include severe gastrointestinal reactions, kidney injury related to volume depletion, gallbladder disease, pancreatitis and hypersensitivity reactions.

Tirzepatide delays gastric emptying. Patients should tell their medical and anesthesia teams that they use a GLP-1/GIP medication before procedures involving general anesthesia or deep sedation.

What About Compounded Tirzepatide?

Compounded tirzepatide is not FDA approved. FDA determined that the national tirzepatide injection shortage was resolved, and the temporary shortage-based enforcement periods for routine copies ended in 2025. In 2026, FDA also proposed excluding tirzepatide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound it from bulk drug substances.

Compounding law allows certain patient-specific circumstances, but compounded products do not undergo FDA premarket review for safety, effectiveness and quality in the same way as FDA-approved Zepbound or Mounjaro. Sanjiva’s educational content distinguishes clearly between FDA-approved tirzepatide products and compounded medications.

Tirzepatide Weight Loss Near You in Dallas

Looking for a tirzepatide doctor near you in Dallas? Sanjiva Medical Spa is located at 5633 W Lovers Lane, Dallas, TX 75209, convenient to University Park, Highland Park, Preston Hollow, Bluffview, Uptown Dallas, Oak Lawn, Greenway Parks and surrounding neighborhoods.

Our differentiator is not simply access to a weight-loss injection. It is medical weight management guided by a physician board certified in both Internal Medicine and Obesity Medicine, combined with body-composition monitoring and individualized treatment planning.

Frequently Asked Questions About Tirzepatide

Is tirzepatide the same as Mounjaro?

Tirzepatide is the active medication in Mounjaro. Mounjaro is FDA approved for type 2 diabetes, while Zepbound is the tirzepatide brand specifically approved for chronic weight management in eligible patients.

Is Zepbound tirzepatide?

Yes. Zepbound contains tirzepatide. It is FDA approved for chronic weight management in qualifying patients and for moderate-to-severe obstructive sleep apnea in adults with obesity.

How much weight can I lose on tirzepatide?

In SURMOUNT-1, average weight reduction at 72 weeks ranged from about 15% to 21% depending on dose using the treatment-regimen estimand. Individual results vary.

Is tirzepatide better than semaglutide?

In the head-to-head SURMOUNT-5 obesity trial, tirzepatide produced greater average weight loss than semaglutide at 72 weeks: 20.2% versus 13.7%. That does not make tirzepatide automatically better for every individual patient.

Does tirzepatide cause muscle loss?

Significant weight loss can include both fat and lean tissue. Adequate protein, resistance training and body-composition monitoring can make preservation of muscle an explicit part of the treatment plan.

How often is Zepbound taken?

Zepbound is administered once weekly. Treatment begins at a low dose and is escalated gradually according to the prescribing information and individual tolerability.

Is compounded tirzepatide FDA approved?

No. Compounded tirzepatide is not FDA approved and is not reviewed by FDA for safety, effectiveness and manufacturing quality before marketing in the same manner as an FDA-approved medication.

Do I have to stay on tirzepatide forever?

Not necessarily, but obesity is a chronic disease and weight regain can occur after medication withdrawal. Maintenance planning should be individualized and discussed as part of treatment rather than after weight loss is complete.

Where can I find tirzepatide weight loss near me in Dallas?

Sanjiva Medical Spa provides physician-guided medical weight management at 5633 W Lovers Lane in Dallas, convenient to University Park, Highland Park, Preston Hollow, Bluffview, Uptown Dallas and Oak Lawn.

Medical Weight Loss Is More Than an Injection

Tirzepatide can be a powerful medical tool, but successful treatment is about more than suppressing appetite. Sanjiva focuses on fat loss, muscle preservation, body composition, medical safety and a realistic long-term strategy.

Praveen Guntipalli, MD, FACP
Medical Director, Sanjiva Medical Spa
Board Certified — American Board of Internal Medicine
Board Certified — American Board of Obesity Medicine

Selected Medical References

Key evidence includes FDA prescribing information and the SURMOUNT clinical-trial program evaluating tirzepatide for obesity and long-term weight management.

  • FDA-approved prescribing information for Zepbound (tirzepatide).
  • Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
  • Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025.
  • FDA regulatory updates regarding GLP-1 compounding and the resolved tirzepatide shortage.
Medical disclaimer: This page is for educational purposes and does not guarantee weight loss or establish that tirzepatide is appropriate for any individual patient. Prescription treatment requires medical evaluation. Brand names are the property of their respective manufacturers. FDA-approved indications differ between tirzepatide products. Individual results vary.
-----------------